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Introduction
============

Epicardial adipose tissue (EAT) has been suggested to be a potential contributing factor for coronary atherosclerosis^[@bib1]--[@bib3])^. EAT is a type of visceral adipose tissue; it has both paracrine and endocrine effects and is known to secret several proatherogenic cytokines^[@bib4])^. Previous cross-sectional studies showed that increased EAT is not only associated with a higher prevalence of coronary artery disease (CAD) but may also be a prognosticator for future cardiovascular events and, eventually, cardiovascular mortality^[@bib5]--[@bib8])^.

The main limitation of previous EAT studies is that most were cross-sectional studies, and therefore, a causal relationship between increased EAT and the progression or development of CAD or coronary plaques cannot be determined^[@bib5],\ [@bib6],\ [@bib9],\ [@bib10])^. Several studies have demonstrated a relationship between EAT and the progression of coronary calcification by serial measurement^[@bib11],\ [@bib12])^, but the impact of EAT on the development of high-risk coronary plaque has not been established. The lack of prospective studies defining a causal relationship between EAT and the development of NCP has resulted in skepticism toward EAT measurement in clinical practice, and EAT is considered only an innocent bystander in the atherogenic process^[@bib13])^.

In this study, we aimed to investigate the impact of EAT on the development of coronary plaque in order to clarify the missing link between EAT and cardiovascular events. We reviewed records of individuals who had undergone cardiac computed tomography (CT) more than two times, and we identified 122 asymptomatic individuals without prior history of CAD, without metabolic syndrome, and without NCP on baseline CT. We used serial cardiac CT performed with an interval of more than 5 years to investigate whether baseline epicardial fat volume (EFV) is associated with the "de novo" development of NCP.

Methods
=======

Study Population
----------------

Between July 2006 and November 2008, we enrolled 162 asymptomatic Korean individuals who underwent general health exams at the Healthcare System Gangnam Center, Seoul National University Hospital and underwent repeat cardiac CT with an interval of at least 5 years between examinations. All subjects were aged 40 years or older and underwent medical examinations and cardiac CT for screening purposes at their requests. Patients with metabolic syndrome as defined according to the World Health Organization\'s criteria (*n* = 8) were excluded^[@bib14])^. Those with NCP or obstructive CAD (≥ 70% stenosis; *n* = 32) at baseline cardiac CT were also excluded in order to assess the predictive value of EFV for the development of de novo NCP at follow-up CT. Patients with a prior history of CAD, metabolic syndrome, clinically significant valvular heart disease, or cardiomyopathy were also excluded. Past medical history and current medications for each patient were obtained from medical questionnaires. Hypertension (HTN) was defined as systolic blood pressure (SBP) greater than or equal to 140 mmHg or diastolic blood pressure (DBP) greater than or equal to 90 mmHg without medication or current antihypertensive therapy. Diabetes mellitus (DM) was defined as fasting blood glucose greater than or equal to 126 mg/dL, hemoglobin A1c (HbA1c) greater than or equal to 6.5%, or use of antidiabetic medications. Dyslipidemia was defined as total cholesterol greater than or equal to 240 mg/dL, triglycerides greater than or equal to 200 mg/dL, low-density lipoprotein cholesterol (LDL-c) greater than or equal to 160 mg/dL, high-density lipoprotein cholesterol (HDL-c) less than 40 mg/dL in men and less than 50 mg/dL in women, or use of lipid-lowering medications. Obesity was defined as a body mass index (BMI) greater than or equal to 25 kg/m^2^, according to the criteria from the World Health Organization\'s Asia-Pacific guideline^[@bib15])^. Central obesity was defined as a waist circumference greater than 102 cm in men and greater than 88 cm in women, according to the current guidelines from the National Cholesterol Education Program (NCEP)^[@bib16])^.

This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the institutional review board of the Healthcare System Gangnam Center, Seoul National University Hospital (IRB No. 1604-009-752).

Anthropometric and Laboratory Parameters
----------------------------------------

Body weight (kg), height (cm), waist circumference (cm), and blood pressures were measured on the day of the medical exam and CT scan. All participants fasted for at least 12 hours before the blood test. Total cholesterol (mg/dL), fasting insulin (µU/mL), triglyceride (mg/dL), HDL-c (mg/dL), LDL-c (mg/dL), fasting blood glucose (mg/dL), HbA1c (%), and high-sensitivity C-reactive protein (hsCRP; mg/L) levels were measured. Homeostatic model assessment for insulin resistance (HOMA-IR) was calculated from fasting glucose and insulin levels using the following equation: HOMA-IR= (fasting blood glucose) × (fasting insulin)/405^[@bib17])^.

Cardiac CT and EAT Measurement
------------------------------

After completion of the medical questionnaire, anthropometric measurements and laboratory tests, cardiac CT was performed using either a 16-slice multidetector CT scanner (Somatom Sensation 16; Siemens Medical Solutions, Forchheim, Germany) or a 256-slice multidetector CT scanner (Brilliance iCT 256; Philips Medical Systems, Cleveland, OH, USA), with electrocardiogram-gated dose modulation. A standard scanning protocol was applied, with 128 × 0.625 mm section collimation, 0.27 ms rotation time, 120 kV tube voltage and 800 mA tube current for the 256-slice multidetector CT and a tube voltage of 120 kV, 170 effective mAs, and 0.37 rotation time for the 16-slice CT. Before cardiac CT, heart rate was measured, and if the heart rate was higher than 60 beats per min, participants received 50--100 mg of metoprolol.

For measurement of EFV, the volume of EAT was measured by two different observers with a dedicated computer 3D station (Rapidia; Infinitt, Seoul, Korea), which was described in our previous publication^[@bib18])^. Segmentation of the pericardial adipose tissue was achieved by isolating the pericardial adipose tissue and heart from the thorax using specific anatomical landmarks. The superior extent of the volume was determined by the center of the right pulmonary artery as it crossed the midsagittal plane. This point was determined by simultaneously visualizing the right pulmonary artery in the axial and sagittal planes. Inferiorly, the analysis volume was segmented at the level where the coronary sinus drained into the right atrium. Each observer had interactive access to the coronal images to aid in this segmentation step. The anterior border of the volume was defined by the sternum. Special care was taken not to include posterior mediastinal and paravertebral adipose tissues. After segmentation of the heart and EAT from the remainder of the thorax, a threshold of -190 to -30 Hounsfield units (HU) was applied to isolate adipose tissue-containing voxels. The voxels were summed to provide a value for the EFV (cm^3^), which was then related to body surface area as the EFV index (EFVi; cm^3^/m^2^).

All participants without NCP at baseline underwent follow-up cardiac CT for screening purposes. Atherosclerotic lesions were classified as NCP (calcified lesions with at least 130 HU that occupied \<50% of the plaque area) and calcified plaque (CP; calcified lesions with at least 130 HU that occupied ≥ 50% of the plaque area). Patients with both NCP and CP or mixed plaques at follow-up CT were categorized as NCP group, given that the presence of NCP, a vulnerable coronary plaque, would indicate a higher risk of future cardiovascular event than that of CP.

Statistical Analysis
--------------------

We categorized participants on the basis of results of the follow-up CT: no plaque (NP) group, CP group, and NCP group. Categorical variables are presented as frequencies and percentages, and continuous variables are presented as means ± standard deviations or medians with interquartile ranges (IQRs) according to the subgroups. We compared categorical variables using *χ*^2^ analysis, and we compared continuous variables using the Student\'s *t*-test and analysis of variance (ANOVA) or the Mann Whitney *U*-test and Kruskall Wallis test, depending on the number of groups assessed. We applied linear regression analysis to evaluate the correlation of EFVi with other baseline parameters. Then, we used multiple linear regression analysis on all variables with *P* values less than 0.200 by univariable analyses in order to examine the determinants of baseline EFVi. The differences in EFVi according to the results of the follow-up CT were further assessed by one-way analysis of covariance (ANCOVA) with post-hoc comparisons using age, sex, HTN, DM, Framingham risk score, BMI, and waist circumference as covariates. Adjusted odds ratios (ORs) for having NCP on follow-up cardiac CT were calculated by multivariable logistic regression models that included univariable predictors with *P* values less than 0.200. We used the tertiles of EFVi for the logistic regression analysis, with the 1st tertile of EFVi as the reference. All statistical analyses were performed with SPSS 20.0 software (SPSS Inc, Chicago, IL). A *P* value less than 0.05 was considered statistically significant.

Results
=======

Baseline Characteristics
------------------------

Among the total 122 participants with EFVi measurements and without NCP at baseline, follow-up CT was performed with a median interval of 65.4 (IQR, 62.3--73.4 months) months after the baseline CT scan. Baseline characteristics of the study population are summarized according to the results of the follow-up CT (**[Table 1](#T1){ref-type="table"}**): NP group (*n* = 50; 41.0%), CP group (*n* = 48; 39.3%), and NCP group (*n* = 24; 19.7%). Compared to the NP group, the CP and NCP groups had older participants and had more males than females. Comorbidities such as HTN, DM, dyslipidemia, and obesity were more common in the CP and NCP groups, than in the NP group. Framingham 10-year risk score was also significantly higher in the CP and NCP groups.

###### Baseline characteristics of participants according to results of follow-up CT

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                    Total\         Follow-up cardiac CT   Overall P                                                                                      
                                                    (*n* = 122)                                                                                                                          
  ------------------------------------------------- -------------- ---------------------- ----------------------------------------------- ---------------------------------------------- ----------
  Age                                               56.04 ± 7.62   53.54 ± 7.75           58.15 ± 7.08^[†](#tfn2){ref-type="table-fn"}^   57.04 ± 7.14                                   0.008

  Age ≥ 65 years                                    18 (14.8%)     3 (6.0%)               11 (22.9%)                                      4 (16.7%)                                      0.059

  Male sex                                          98 (80.3%)     35 (70.0%)             42 (87.5%)                                      21 (87.5%)                                     0.057

  HTN                                               49 (40.2%)     17 (34.0%)             19 (39.6%)                                      13 (54.2%)                                     0.252

  DM                                                11 (9.0%)      1 (2.0%)               3 (6.2%)                                        7 (29.2%)                                      \< 0.001

  Dyslipidemia                                      21 (17.2%)     5 (10.0%)              11 (22.9%)                                      5 (20.8%)                                      0.208

  Smoking                                                                                                                                                                                0.519

  \- Never                                          45 (36.9%)     21 (42.0%)             14 (29.2%)                                      10 (41.7%)                                     

  \- Ex-smoker                                      54 (44.3%)     19 (38.0%)             26 (54.2%)                                      9 (37.5%)                                      

  \- Current smoker                                 23 (18.9%)     10 (20.0%)             8 (16.7%)                                       5 (20.8%)                                      

  SBP (mmHg)                                        120.7 ± 14.7   119.9 ± 15.0           119.6 ± 14.1                                    124.1 ± 15.4                                   0.450

  DBP (mmHg)                                        78.2 ± 10.9    76.1 ± 11.6            79.1 ± 10.4                                     80.9 ± 11.7                                    0.169

  Height (cm)                                       167.3 ± 8.2    165.6 ± 9.0            168.7 ± 7.7                                     168.3 ± 7.0                                    0.157

  Weight (kg)                                       69.8 ± 10.0    67.8 ± 10.0            70.6 ± 9.3                                      72.4 ± 10.9                                    0.149

  BMI (kg/m^2^)                                     24.9 ± 2.6     24.7 ± 2.7             24.8 ± 2.5                                      25.5 ± 2.8                                     0.436

  BMI ≥ 25 kg/m^2^                                  53 (43.4%)     24 (48.0%)             20 (41.7%)                                      9 (37.5%)                                      0.661

  BSA (m^2^)                                        1.79 ± 0.16    1.76 ± 0.17            1.81 ± 0.15                                     1.82 ± 0.17                                    0.246

  Waist circumference (cm)                          89 ± 7         88 ± 7                 89 ± 7                                          91 ± 7                                         0.318

  Central obesity[\*](#tfn1){ref-type="table-fn"}   10 (8.2%)      5 (10.0%)              3 (6.2%)                                        2 (8.3%)                                       0.795

  Framingham 10-yr risk score (%)                   6 (3--10)      4 (2--8)               8 (4--11)^[†](#tfn2){ref-type="table-fn"}^      7 (3--12)^[‡](#tfn3){ref-type="table-fn"}^     0.002

  Framingham score ≥ 10%                            35 (28.7%)     7 (14.0%)              20 (41.7%)                                      8 (33.3%)                                      0.009

  Total cholesterol (mg/dL)                         195.7 ± 31.4   194.9 ± 32.1           198.7 ± 31.0                                    191.7 ± 31.5                                   0.675

  Triglyceride (mg/dL)                              122.2 ± 61.6   124.8 ± 72.9           112.0 ± 42.4                                    135.9 ± 65.7                                   0.299

  HDL cholesterol (mg/dL)                           53.8 ± 13.2    54.4 ± 14.2            54.0 ± 12.2                                     52.2 ± 13.3                                    0.808

  LDL cholesterol (mg/dL)                           118.0 ± 30.9   115.9 ± 32.6           123.2 ± 29.2                                    112.7 ± 30.2                                   0.345

  Creatinine (mg/dL)                                1.09 ± 0.16    1.08 ± 0.18            1.10 ± 0.15                                     1.11 ± 0.13                                    0.672

  GFR (ml/min/1.73 m^2^)                            73.2 ± 10.1    73.7 ± 10.9            72.7 ± 9.1                                      73.0 ± 10.5                                    0.900

  HbA1c (%)                                         5.95 ± 0.67    5.87 ± 0.49            5.91 ± 0.52                                     6.19 ± 1.12                                    0.174

  FBS (mg/dL)                                       98.7 ± 11.1    98.0 ± 10.1            98.8 ± 12.6                                     100.2 ± 10.4                                   0.796

  Fasting insulin (µU/mL)                           10.57 ± 4.84   9.60 ± 3.85            11.60 ± 6.00                                    10.73 ± 3.92                                   0.357

  HOMA-IR                                           2.20 ± 1.25    1.98 ± 0.89            2.40 ± 1.62                                     2.40 ± 1.18^[‡](#tfn3){ref-type="table-fn"}^   0.440

  hsCRP (mg/L)                                      1.13 ± 1.82    1.10 ± 1.21            1.28 ± 2.39                                     0.95 ± 1.70                                    0.808

  Follow-up duration (months)                       65 (62--73)    65 (63--73)            65 (62--73)                                     66 (63--74)                                    0.916
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are shown as mean ± standard deviation, median (interquartile range), or proportions (%). *P* values were calculated by analysis of covariance with post-hoc comparisons.

Central obesity: waist circumference \>120 cm in men and \>88 cm in women, according to the guidelines of NCEP ATP III^[@bib16])^.

*P* \< 0.01 versus "No plaque" group

*P* \< 0.05 versus "No plaque" group

Abbreviations: CT, computed tomography; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; BSA, body surface area; HOMA-IR, homeostatic model assessment insulin resistance index; hsCRP, high-sensitivity C-reactive protein.

Determinants of Epicardial Fat Volume
-------------------------------------

To examine the determinants of baseline EFVi, we used linear regression analysis for the EFVi values and logistic regression analysis for the 3rd tertile of EFVi, among the univariable predictors with *p* values \<0.200 (**[Table 2](#T2){ref-type="table"}** and **[Supplementary Table 1](#T5){ref-type="table"}**). For the EFVi values, age (B = 0.761; 95% CI, 0.116--1.407; *P* = 0.021 per 1-year increase) and BMI (B = 4.055; 95% CI, 0.836--7.274; *P* = 0.014 per 1 kg/m^2^ increase) were significant determinants (**[Table 2](#T2){ref-type="table"}**). Similarly, analysis for the 3rd tertile of baseline EFVi showed that advanced age and higher BMI were significant determinants (**[Supplementary Table 1](#T5){ref-type="table"}**).

###### Multiple linear regression analysis for baseline epicardial fat volume index

                                    Univariable   Multivariable                                        
  --------------------------------- ------------- ---------------- --------- -------- ---------------- -------
  Age (per + 1 year)                0.563         −0.052--1.179    0.072     0.761    0.116--1.407     0.021
  Male sex                          3.557         −8.330--15.445   0.555                               
  HTN                               6.370         −3.214--15.955   0.191     2.657    −6.783--12.097   0.578
  DM                                6.583         −9.897--23.063   0.431                               
  Dyslipidemia                      4.037         −8.478--16.552   0.524                               
  Current smoker                    −5.817        −17.871--6.236   0.341                               
  BMI (kg/m^2^)                     4.977         3.332--6.622     \<0.001   4.055    0.836--7.274     0.014
  Waist circumference (cm)          1.797         1.162--2.432     \<0.001   0.330    −0.900--1.560    0.596
  Framingham 10-yr risk score (%)   0.949         −0.104--2.002    0.077     −0.036   −1.237--1.166    0.953
  Total cholesterol (mg/dL)         0.056         −0.100--0.213    0.479                               
  Triglyceride (mg/dL)              −0.001        −0.081 -0.079    0.985                               
  LDL-C (mg/dL)                     0.129         −0.028--0.287    0.107     0.120    −0.029--0.270    0.113
  HDL-C (mg/dL)                     −0.300        −0.669--0.068    0.109     −0.072   −0.434--0.289    0.692
  HOMA-IR                           3.141         −0.879--7.161    0.124     −0.294   −5.360--4.771    0.908
  hsCRP (mg/L)                      1.526         −1.837--4.888    0.369                               

Abbreviations: HTN, hypertension; DM, diabetes mellitus; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment insulin resistance index; hsCRP, high-sensitivity C-reactive protein.

###### Multivariable logistic regression analysis for the 3rd tertile of baseline epicardial fat volume index

                                    Univariable   Multivariable^[†](#tfn13){ref-type="table-fn"}^                                    
  --------------------------------- ------------- ------------------------------------------------- --------- ------- -------------- -------
  Age (per + 1 year)                1.060         1.006--1.116                                      0.028     1.133   1.016--1.265   0.025
  Male sex                          0.808         0.319--2.044                                      0.653                            
  HTN                               1.708         0.797--3.661                                      0.169     0.808   0.194--3.365   0.770
  DM                                2.606         0.745--9.118                                      0.134     0.454   0.053--3.927   0.474
  Dyslipidemia                      1.617         0.619--4.226                                      0.327                            
  Current smoker                    1.067         0.411--2.770                                      0.895                            
  BMI (kg/m^2^)                     1.795         1.407--2.289                                      \<0.001   1.718   1.031--2.865   0.038
  Waist circumference (cm)          1.206         1.109--1.310                                      \<0.001   1.101   0.905--1.339   0.338
  Framingham 10-yr risk score (%)   1.093         1.003--1.190                                      0.042     1.016   0.852--1.213   0.857
  Total cholesterol (mg/dL)         1.006         0.993--1.018                                      0.367                            
  Triglyceride (mg/dL)              1.000         0.993--1.006                                      0.913                            
  LDL-C (mg/dL)                     1.020         0.997--1.023                                      0.120     1.013   0.989--1.037   0.282
  HDL-C (mg/dL)                     0.988         0.959--1.018                                      0.412                            
  HOMA-IR                           1.399         0.990--1.976                                      0.057     0.958   0.527--1.742   0.888
  hsCRP (mg/L)                      7.376         0.600--90.681                                     0.119     1.099   0.769--1.572   0.604

Central obesity: waist circumference \>120 cm in men and \>88 cm in women, according to the guidelines of NCEP ATP III.

Low HDL-C: HDL-C levels \<40 mg/dL in men and \<50 mg/dL in women, according to the guidelines of NCEP ATP III.

adjustment with age (per + 1 year), HTN, DM, BMI (per + 1 kg/m^2^), waist circumference (per + 1 cm), Framingham 10-year risk score (per + 1%), LDL-C (per + 1 mg/dL), HOMA-IR and hsCRP (per + 1 mg/L).

Abbreviations: HTN, hypertension; DM, diabetes mellitus; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment insulin resistance index; hsCRP, high-sensitivity C-reactive protein.

Differences in EFV According to Follow-up CT Results
----------------------------------------------------

In the total population, the mean EFV at baseline was 120.1 ± 49.5 cm^3^, and the mean of EFVi was 66.4 ± 25.8 cm^3^/m^2^ (**[Table 3](#T3){ref-type="table"}**). Baseline EFVi was significantly different between subgroups according to the follow-up CT results, but the follow-up EFVi and changes in EFVi from baseline to follow-up were not different between the subgroups. The difference in baseline EFVi between subgroups remained significant even after adjusting for age, sex, HTN, DM, Framingham risk score, and obesity as covariates (adjusted overall *P* = 0.013; **[Fig. 1](#F1){ref-type="fig"}**). In the NCP group, the baseline EFVi was 79.9 ± 30.3 cm^3^/m^2^, which was significantly higher than in the NP group (62.5 ± 24.7 cm^3^/m^2^; adjusted *P* = 0.019) and in the CP group (63.7 ± 22.7 cm^3^/m^2^; adjusted *P* = 0.021).

###### Baseline and follow-up EFV and EFVi levels according to follow-up CT results

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
                      Total\           Follow-up cardiac CT   Overall P                                                                                          
                      (*n* = 122)                                                                                                                                
  ------------------- ---------------- ---------------------- ---------------- --------------------------------------------------------------------------------- -------
  EFV (cm^3^)                                                                                                                                                    

  \- Baseline         120.12 ± 49.48   110.95 ± 45.80         116.74 ± 46.27   146.00 ± 55.96[\*](#tfn4){ref-type="table-fn"}^[†](#tfn5){ref-type="table-fn"}^   0.013

  \- Follow-up        125.97 ± 53.93   119.39 ± 50.61         122.35 ± 55.59   146.93 ± 54.33                                                                    0.100

  \- Change           5.85 ± 2.65      8.43 ± 2.94            5.61 ± 2.64      0.93 ± 1.96                                                                       0.524

  \- Change (%)       7.36 ± 24.26     12.12 ± 29.43          5.17 ± 21.53     1.81 ± 14.57                                                                      0.168

                                                                                                                                                                 

  EFVi (cm^3^/m^2^)                                                                                                                                              

  \- Baseline         66.41 ± 25.84    62.52 ± 24.72          63.71 ± 22.71    79.93 ± 30.30[\*](#tfn4){ref-type="table-fn"}^[†](#tfn5){ref-type="table-fn"}^    0.016

  \- Follow-up        69.97 ± 28.13    67.37 ± 27.28          67.01 ± 27.53    81.28 ± 29.37                                                                     0.094

  \- Change           3.52 ± 14.57     4.86 ± 16.54           3.27 ± 14.04     1.23 ± 11.03                                                                      0.601

  \- Change (%)       7.52 ± 23.48     11.98 ± 28.92          5.38 ± 20.29     2.51 ± 14.04                                                                      0.193
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are shown as mean ± standard deviation (SD). *P* values were calculated by ANOVA with post-hoc comparisons.

*P* \< 0.05 versus "No plaque" group

*P* \< 0.05 versus "Calcified plaque" group

Abbreviations: CT, computed tomography; EFV, epicardial fat volume; EFVi, epicardial fat volume index.

![Differences in EFVi according to follow-up CT results\
Baseline EFVi was significantly higher in participants who had NCP on follow-up CT than participants who had CP or no plaque on follow-up CT. *P*-values were calculated by ANCOVA with age, sex, HTN, DM, Framingham risk score, BMI, and central obesity as covariates.\
Abbreviations: EFVi, epicardial fat volume index; CT, computed tomography; HTN, hypertension; DM, diabetes mellitus; NCP, non-calcified plaque; CP, calcified plaque; ANCOVA, analysis of covariance; BMI, body mass index.](jat-24-262-g001){#F1}

Impact of EFV on the Development of NCP
---------------------------------------

**[Fig. 2](#F2){ref-type="fig"}** shows that there were significant differences in the proportions of participants in the NP, CP, and NCP groups in each tertile of baseline EFVi (overall *P* = 0.038). Among the participants in the 3rd tertile of baseline EFVi, 11 participants (29.3%) had NCP on the follow-up CT; 14 participants (22.5%) who were in the 2nd tertile at baseline and 16 participants (7.3%) who were in the 1st tertile at baseline had NCP on the follow-up CT (3rd tertile vs. 1st tertile, *P* = 0.020; 2nd tertile vs. 1st tertile, *P* = 0.067).

![Impact of EFVi on the development of coronary plaque\
The development of NCP on follow-up CT was observed more frequently among participants with increased EFVi at baseline. *P*-values were calculated by the *χ*^2^ test.\
Abbreviations: EFV, epicardial fat volume; CT, computed tomography; NCP, non-calcified plaque.](jat-24-262-g002){#F2}

We investigated baseline characteristics and baseline EFVi as potential contributing factors for the development of NCP on follow-up CT (**[Table 4](#T4){ref-type="table"}**). In the univariable logistic regression analysis, baseline EFVi was significantly associated with NCP on follow-up CT (OR, 1.024; 95% CI, 1.006-- 1.042; *P* = 0.008 per 1 cm^3^/m^2^ increase). When the 1st tertile of baseline EFVi was used as the reference group, the 2nd tertile had an OR of 3.677 (95% CI, 0.916--14.765; *P* = 0.066), and the 3rd tertile had an OR of 5.241 (95% CI, 1.353--20.306; *P* = 0.017). After adjusting for the univariable factors with a *P* value of less than 0.200, the baseline EFVi values and the 3rd tertile of EFVi were significantly associated with the development of NCP. The predictive value of the 3rd tertile of baseline EFVi was maintained even after adjusting for age, sex, HTN, DM, dyslipidemia, smoking status, obesity, central obesity, and Framingham risk score (OR, 4.297; 95% CI, 1.040 --17.757; *P* = 0.044).

###### Factors that contribute to the presence of non-calcified coronary plaque on follow-up CT

                                                                Univariable   Multivariable Model 1^[‡](#tfn9){ref-type="table-fn"}^   Multivariable Model 2^[§](#tfn10){ref-type="table-fn"}^                                                           
  ------------------------------------------------------------- ------------- -------------------------------------------------------- --------------------------------------------------------- ------- --------------- ------- ------- --------------- -------
  Age (per + 1 year)                                            1.021         0.964--1.082                                             0.472                                                                                                             
  Age ≥ 65 years                                                1.200         0.357--4.038                                             0.768                                                                                                             
  Male sex                                                      1.909         0.519--7.022                                             0.331                                                                                                             
  HTN                                                           2.035         0.826--5.016                                             0.122                                                     1.513   0.558--4.106    0.416   1.712   0.561--5.222    0.345
  DM                                                            9.767         2.552--36.685                                            0.001                                                     8.911   2.235--35.531   0.002   9.081   1.682--49.034   0.010
  Dyslipidemia                                                  1.349         0.439--4.139                                             0.601                                                                                                             
  Current smoker                                                1.170         0.385--3.549                                             0.782                                                                                                             
  BMI (kg/m^2^)                                                 1.123         0.939--1.342                                             0.203                                                                                                             
  BMI ≥ 25 kg/m^2^                                              0.736         0.294--1.843                                             0.513                                                                                                             
  Waist circumference (cm)                                      1.041         0.973--1.114                                             0.241                                                                                                             
  Central obesity[\*](#tfn6){ref-type="table-fn"}               1.023         0.203--5.158                                             0.978                                                                                                             
  Framingham 10-yr risk score (%)                               1.065         0.966--1.175                                             0.206                                                                                                             
  Framingham risk score \<10%                                   1.315         0.505--3.425                                             0.575                                                                                                             
  Total cholesterol (mg/dL)                                     0.995         0.980--1.010                                             0.496                                                                                                             
  Triglyceride (mg/dL)                                          1.004         0.997--1.011                                             0.238                                                                                                             
  LDL-C (mg/dL)                                                 0.993         0.978--1.008                                             0.355                                                                                                             
  LDL-C ≥ 160 mg/dL                                             0.307         0.038--2.490                                             0.269                                                                                                             
  HDL-C (mg/dL)                                                 0.988         0.953--1.024                                             0.518                                                                                                             
  Low HDL-C[\*\*](#tfn7){ref-type="table-fn"}                   1.095         0.326--3.677                                             0.884                                                                                                             
  HOMA-IR                                                       1.082         0.647--1.811                                             0.763                                                                                                             
  HOMA-IR \<2.0                                                 1.600         0.471--5.440                                             0.452                                                                                                             
  HOMA-IR \<2.5                                                 1.833         0.555--6.055                                             0.320                                                                                                             
  hsCRP (mg/L)                                                  0.919         0.669--1.262                                             0.602                                                                                                             
  hsCRP ≥ 1.0 mg/L                                              0.626         0.213--1.842                                             0.395                                                                                                             
  hsCRP ≥ 2.0 mg/L                                              0.981         0.280--3.435                                             0.976                                                                                                             
  Baseline EFVi (cm^3^/m^2^)^[†](#tfn8){ref-type="table-fn"}^   1.024         1.006--1.042                                             0.008                                                     1.024   1.005--1.043    0.012                           
  \- Tertile 1                                                  Ref                                                                                                                                                              Ref                     
  \- Tertile 2                                                  3.677         0.916--14.765                                            0.066                                                                                     3.606   0.844--15.402   0.083
  \- Tertile 3                                                  5.241         1.353--20.306                                            0.017                                                                                     4.297   1.040--17.757   0.044

Central obesity: waist circumference \>120 cm in men and \>88 cm in women, according to the guidelines of NCEP ATP III^[@bib16])^.

Low HDL-C: HDL-C levels \<40 mg/dL in men and \<50 mg/dL in women, according to the guidelines of NCEP ATP III^[@bib16])^.

EFVi values were used as a continuous variable in multivariable model 1, and as categorical variables in multivariable model 2; the 1st tertile of EFVi was used as the reference group.

Model 1: adjustment for HTN, DM and baseline EFVi.

Model 2: adjustment for HTN, DM and tertiles of baseline EFVi (1st tertile as reference).

Abbreviations: CT, computed tomography; OR, odds ratio; HTN, hypertension; DM, diabetes mellitus; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment insulin resistance index; hsCRP, high-sensitivity C-reactive protein; EFVi, epicardial fat volume index.

Discussion
==========

Among 122 participants without prior history of CAD and without metabolic syndrome, high EFVi was an independent risk factor for the future development of NCP even after adjustment for traditional cardiovascular risk factors. Given the scarce previous research on the impact of EAT on the "de novo" development of NCP over enough time interval and the lack of direct evidence on the causal relationship between EAT and vulnerable coronary plaque, this study of repeat CT scans among individuals in preclinical stage provides novel implications for cardiovascular prevention and screening. Our findings expand current knowledge related to EAT and cardiovascular risk and reveal that excessive EAT promotes the development of high-risk coronary plaque, which may further contribute to a higher risk of cardiovascular events.

EAT: a Potential Promoter of Coronary Atherosclerosis
-----------------------------------------------------

EAT refers to the brown adipose tissue located between the myocardium and pericardium; it originates embryologically from the splanchno-pleuric mesoderm associated with the gut^[@bib2],\ [@bib19],\ [@bib20])^. Compared to white adipose tissue, which has the primary function of storing triglycerides and free fatty acids, EAT is more metabolically active and has distinctive features such as the expression of adiponectin and inflammatory cytokines^[@bib1],\ [@bib4],\ [@bib21])^. Because there is no separation by a physical fascia, EAT has direct contact with the surface of the myocardium and coronary vessels, and therefore, it is reasonable to assume that EAT could influence coronary atherosclerosis through local paracrine interactions^[@bib1],\ [@bib22])^.

Current understandings of the pathophysiology of EAT and atherosclerosis were strengthened by cross-sectional studies that revealed independent associations between increased EAT and the presence of CAD^[@bib9],\ [@bib23],\ [@bib24])^. Moreover, several serial studies demonstrated that increased baseline EAT volume was associated with the progression or new development of coronary artery calcification (CAC). In a study by Nakanishi *et al.*, 375 consecutive subjects underwent serial CAC measurements at least 3 to 5 years apart, and the findings revealed that increased EFV was associated with greater progression of CAC and with the development of calcified plaque^[@bib11])^. Another study of serial CAC measurements by Yerramasu *et al.* also reported the independent predictive value of EAT volume for CAC progression^[@bib12])^.

In the present study, we showed that baseline EAT was not associated with future development of CP, which may seem conflicting with the aforementioned study results. However, our findings are not against the current evidence on the relationship between EAT and coronary calcification. Although the exact pathophysiologic mechanisms by which EAT causes atherosclerosis are not completely understood yet, growing evidence suggest that EAT promotes the early stages of atherosclerotic plaque formation: proinflammatory and inflammatory cytokines that are produced and secreted by EAT, such as interleukin-1, interleukin-6, tumor necrosis factor (TNF) and monocyte chemoattractant protein 1 (MCP-1), proinflammatory M1 macrophages in EAT, increased oxidative stress, and accumulation of lipids are the potential mechanisms^[@bib25])^. In accordance with those preclinical findings, recent studies suggested that EAT might be associated with vulnerable plaque independent of coronary calcification^[@bib26],\ [@bib27])^. Since our study focused on the development of NCP rather than overall calcification, our findings are still in line with previous studies in terms of association between EAT and coronary atherosclerosis. Moreover, our findings have an important clinical significance for the following practical reason.

From the viewpoint of risk prediction and prevention, the usefulness of EAT measurement merely for the prediction of CAC is limited because CAC burden is an indirect reflection of the atherosclerotic process rather than a causative lesion. It should be noted that the presence and progression of CAC cannot always be regarded as direct evidence of cardiovascular risk, since calcification in coronary arteries not only reflects the atherosclerotic process but suggests stable plaque in advanced stages of atherosclerosis^[@bib28],\ [@bib29])^. Moreover, according to recent studies, the progression of CAC seems to be an inevitable process^[@bib9])^, and the use of statin therapy may accelerate coronary calcification^[@bib19],[@bib22])^. Therefore, the relationship between EAT and CAC progression does not support the usefulness of EAT measurement as a determinant of cardiovascular risk or prevention. The direct relationship between EAT and the development of NCP, which is a vulnerable coronary plaque, has required further confirmation.

EAT and the Development of NCP: A Missing Link between the Pathobiologic Process and Clinical Practice
------------------------------------------------------------------------------------------------------

Growing evidence suggests a causal relationship between EAT and cardiovascular risk, but there is no evidence or investigation by serial measurement to support the actual impact of EAT on the development of vulnerable coronary plaque. In a study of intravascular ultrasound (IVUS) examinations, increased EAT volume was significantly associated with necrotic plaque tissue^[@bib30])^. Other studies of cardiac CT also showed that higher EAT volume was associated with the presence of NCP^[@bib31],\ [@bib32])^. However, these were cross-sectional studies that cannot infer a causal relationship. The lack of evidence of the relationship between EAT and NCP can be attributed to the pathogenesis of coronary atherosclerosis. Because the development of NCP is rarer than that of CAC and the detection of incident NCP requires longer follow-up periods and larger study populations, most evidence has focused on the development and progression of CAC.

Clinically, the relationship between EAT and NCP development will enhance the additive prognostic value of EAT and will support the use of EAT measurement in practice. EAT is associated with the presence of diabetes, obesity, and metabolic syndrome, so it could be argued that EAT is simply an indicator of atherogenic burden. The counter-arguments against the use of EAT as a measure of disease prevention also include questions of the clinical usefulness of EAT beyond the current available measures such as CAC, myocardial perfusion imaging, and other vascular indices^[@bib8],\ [@bib33])^. If the amount of EAT merely reflects the burden of coronary calcification rather than the direct pathogenesis of coronary atherosclerosis, the measurement of EAT in clinical practice will be significantly limited. Furthermore, the prognostic value of EAT over current CAC measurement is debated^[@bib8],\ [@bib33])^. For EAT measurements to be applied in clinical practice, the connection between the pathobiologic process of EAT and the development of NCP, which actually contributes to cardiovascular events, needs to be clarified, particularly in a serial-measurement study design.

In this study, we showed that baseline EFVi is associated with future development of NCP. The predictive value of EFVi for the development of NCP was significant, even after adjusting for age, BMI, and other traditional cardiovascular risk factors such as waist circumference, HTN, diabetes, dyslipidemia, and Framingham 10-year risk score. Our findings support a causal relationship between EAT and NCP, which indicates that excessive EAT is not only a measure of current metabolic status but an independent prognostic factor for the development of vulnerable coronary plaques.

Clinical Implications and Future Directions
-------------------------------------------

Recent cross-sectional studies showed that, among patients with a CAC score of zero, EAT measurement would have a clinical role in the detection of NCP, which cannot be detected on a CAC scan^[@bib31])^. Further, increased EAT volume is associated with necrotic plaque tissue^[@bib30])^. In addition to the previous studies, we demonstrated a novel clinical evidence of a causal relationship between EAT and the development of vulnerable coronary plaque. Our findings suggest the clinical usefulness of EAT measurement for risk stratification and its application in preventive measures and support the additional prognostic value of EAT. As a screening tool, EAT measurement would provide simple but important clinical information on the future risk of NCP development and cardiovascular events, especially among asymptomatic individuals.

However, further studies are needed to investigate whether the action mechanism of preventive medications, such as statins, involves the modification of EAT. It has been well-established that the use of statin therapy can reduce the progression of coronary atherosclerosis and stabilize the vulnerability of plaque, all of which contribute to a better prognosis^[@bib34],\ [@bib35])^. Several studies also suggested that the use of statin may lead to a regression of EAT^[@bib36],\ [@bib37])^. Together with the findings of our study, contemporary evidence indicates that it would be worth to investigate whether the benefit of statin therapy through atherosclerosis modulation effect is associated with any changes in EAT. More importantly, it needs to be validated in prospective trials whether preventive therapies guided by EAT measurement could improve clinical outcomes.

Another important clinical issue is the presence of diabetes, which is a well-known risk factor for coronary atherosclerosis and was an independent predictor of NCP development in the present study. Considering the previous studies that showed a relationship between the presence of diabetes or insulin resistance and increased EAT^[@bib38],\ [@bib39])^, it can be assumed that the association between EAT and NCP development in our study might be an epiphenomenon or secondary to the atherogenic effect of diabetes. However, we showed that the increased EAT is an independent predictor of future NCP development, even after adjustment for the presence of diabetes. Also, the level of HOMA-IR was neither significantly higher in NCP group than in the other groups nor an independent predictor of NCP. The interpretation of this finding needs caution, because we excluded the patients with metabolic syndrome from our study population given the strong relationship between EAT and metabolic syndrome^[@bib25],\ [@bib38],\ [@bib40])^. Therefore, our results should be interpreted as indicating the significant predictive value of EAT for the development of vulnerable plaque but not as suggesting that insulin resistance is not associated with EAT or NCP.

Limitations
-----------

Our study has several limitations. First, we could not use imaging methods such as IVUS or optical coherence tomography (OCT) to obtain detailed information of each coronary plaque. However, it should be noted that the study participants were asymptomatic and underwent CCTA as part of a routine healthcare check-up. Because the invasive assessment of coronary plaque confers potential risks, evaluation by IVUS or OCT was determined to be unethical for our study design. Second, we could not evaluate the impact of location-specific EAT on the development of plaques in adjacent coronary arteries. Current evidence suggests an association between the location-specific EAT thickness at the atrioventricular groove and the presence of obstructive CAD^[@bib41])^, so evaluation of this relationship would provide interesting insight regarding the pathobiology of EAT on the development of coronary atherosclerosis. Third, we excluded participants with metabolic syndrome from this study, since there is a strong relationship between the presence of metabolic syndrome and EAT. The main purpose of this study was to investigate the causal relationship between EAT and the development of NCP, and our findings addressed this association. Because patients with metabolic syndrome or obesity are the populations of interest for the application of EAT measurement, further studies are required to validate the clinical usefulness of EAT measurement in these populations. Last, our study population consisted of relatively healthy subjects with low risk, and ethical issues may arise from using EAT measurement as a screening tool, unless more evidence confirms substantial gain from undergoing cardiac CT. Radiation doses from cardiac CT have been lowered recently, but there is still marginal exposure to radiation; contrast agent hypersensitivity should also be considered as an additional safety issue.

Conclusions
===========

Among 122 asymptomatic individuals without prior history of CAD and without metabolic syndrome, a high EAT volume at baseline was an independent risk factor for NCP development. The prognostic value of a high EAT volume index for vulnerable coronary plaque was significant even after adjusting for traditional risk factors, BMI, and central obesity. Our findings from serial CT scans suggest a causal relationship between EAT and NCP and support the clinical usefulness of EAT measurement.
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